A chamber wall is printed with silicon-based bioink on a sterile glass slide (1). Within this chamber, a mixture of human vascular cells derived from umbilical cords and decellularized extracellular matrix (ECM) from a pig’s brain is printed in a ring (2). Finally, a third bioink, containing porcine ECM combined with glioblastoma (GBM) cells taken from a patient’s resected tumor, fills in the ring (3). After a week of growth in a cell culture incubator, the model is ready to be used to screen various therapy options.
© Kelly Finan
Read the full story.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
